2021

1. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

   Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

2. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

   Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326

3. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

   Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999